Potential role of lampalizumab for treatment of geographic atrophy

William Rhoades, Drew Dickson, Diana V. Do

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.

Original languageEnglish (US)
Pages (from-to)1049-1056
Number of pages8
JournalClinical Ophthalmology
StatePublished - Jun 11 2015


  • AMD
  • Age-related macular degeneration
  • Complement inhibition

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Potential role of lampalizumab for treatment of geographic atrophy'. Together they form a unique fingerprint.

Cite this